Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia

1 Oct 2005

Abstract excerpt

Chronic myeloid leukemia (CML) starts with the acquisition of a BCR-ABL fusion gene in a single hematopoietic stem cell, but the time to progression is unpredictable. Although the tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of CML, its continuous administration is associated with development of resistance, particularly in advanced phase or blast crisis. We investigate here...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16204063
DOI: 10.1158/0008-5472.can-05-0076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid LeukemiaPMID 16204063Read ↗

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibSemantic proximity Read ↗

Chronic myeloid leukemia blast crisis arises from progenitors.Semantic proximity Read ↗

BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?Semantic proximity Read ↗

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administrationSemantic proximity Read ↗

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.Semantic proximity Read ↗

BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemiaSemantic proximity Read ↗

Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.Semantic proximity Read ↗

Consequences of BCR‐ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Molecular mechanisms of resistance of leukemia to imatinib mesylate.Semantic proximity Read ↗

Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progressionSemantic proximity Read ↗

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaSemantic proximity Read ↗

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.